  Significant progress has been made in the treatment of stage iv non-small-cell lung cancer ( nsclc); however , the prognosis of patients with brain metastases remains poor. Resection and radiation therapy remain standard options. This issue is an important one because 10 % of patients with nsclc have brain metastases at diagnosis , and 25 % -40 % develop brain metastases during their disease. Standard chemotherapy does not cross the blood-brain barrier. However , there is new hope that tyrosine kinase inhibitors ( tkis) used in patients with identified targetable mutations such as mutations of